Advocate Group LLC Increases Stake in Pfizer Inc. (NYSE:PFE)

Advocate Group LLC raised its position in Pfizer Inc. (NYSE:PFE) by 4.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 235,508 shares of the biopharmaceutical company’s stock after purchasing an additional 10,548 shares during the period. Pfizer accounts for approximately 1.5% of Advocate Group LLC’s portfolio, making the stock its 23rd biggest holding. Advocate Group LLC’s holdings in Pfizer were worth $6,780,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. State Street Corp raised its holdings in shares of Pfizer by 1.9% during the 2nd quarter. State Street Corp now owns 287,201,692 shares of the biopharmaceutical company’s stock worth $10,534,558,000 after acquiring an additional 5,374,611 shares during the period. Moneta Group Investment Advisors LLC raised its holdings in shares of Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after acquiring an additional 160,963,976 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after acquiring an additional 9,393,992 shares during the period. Morgan Stanley raised its holdings in shares of Pfizer by 0.4% during the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after acquiring an additional 348,628 shares during the period. Finally, Norges Bank purchased a new position in shares of Pfizer during the 4th quarter worth $3,150,472,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of several analyst reports. UBS Group reduced their price target on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a report on Thursday, December 14th. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Barclays reduced their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a report on Thursday, December 14th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Truist Financial reduced their price objective on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 14th. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Trading Down 0.1 %

NYSE PFE traded down $0.03 during trading on Friday, hitting $27.75. The stock had a trading volume of 40,466,657 shares, compared to its average volume of 47,662,984. The company has a market capitalization of $157.14 billion, a PE ratio of 77.08, a PEG ratio of 1.24 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm has a 50 day moving average price of $27.45 and a 200 day moving average price of $29.45. Pfizer Inc. has a twelve month low of $25.61 and a twelve month high of $42.22.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the previous year, the company posted $1.14 earnings per share. The business’s revenue for the quarter was down 41.3% on a year-over-year basis. As a group, equities research analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.